DOCSLIB.ORG

Recent Advances That Are Redefining Oncology

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Recent Advances That Are Redefining Oncology Features Practice Changers Recent advances that are redefining oncology Jane de Lartigue ince President Richard Nixon declared war Small-molecule inhibitors on cancer more than 40 years ago, there have The most easily “druggable” targets for small-molecule Sbeen significant increases in the number of inhibitors (SMIs) are kinases, particularly cell surface people who survive cancer. Alongside advances in tyrosine kinase receptors, which initiate signaling cas- screening, detection, and diagnosis, the develop- cades that drive important cellular processes. SMIs dif- ment of targeted anticancer agents has been a fer from mAbs in that they are administered orally major contributory factor to this success. We rather than intravenously, are less specific, and require highlight some of the key developments that have more frequent dosing. shaped oncological practice in recent decades and Imatinib was the first agent of this kind and those that will likely have a significant impact in was also the first to target a specific molecular the near future (Figure 1). defect in cancer cells; a chromosomal translocation (Philadelphia chromosome) that resulted in the Top 5 therapeutic developments formation of the BCR-ABL fusion protein, a ty- Monoclonal antibodies rosine kinase that is always active and therefore Monoclonal antibodies (mAbs) are designed to oncogenic. This defect is present in almost all specifically kill cancer cells by targeting tumor- patients with chronic myelogenous leukemia, so associated antigens on their surface (Table 1). The imatinib therapy results in a complete hematologic first drug of this kind to be approved by the Food response in 98% of patients. Imatinib has also and Drug Administration (FDA) was rituximab. revolutionized the treatment of gastrointestinal stromal tumors, a rare abdominal cancer that was This anti-CD20 mAb has revolutionized the treat- 2 ment of B-cell lymphomas (on which the CD20 virtually untreatable before its approval. There are at least 90 tyrosine kinases in the human antigen is expressed), producing response rates over 4 90% in combination with the CHOP (cyclophos- genome and many of these have now been targeted phamide, doxorubicin, vincristine, prednisolone) with inhibitors that are either approved (Table 2)orin chemotherapy regimen.1 various stages of development. There have also been notable advances in the Conjugated drugs use of mAbs in the treatment of solid tumors. Chemotherapy and radiotherapy remain impor- Trastuzumab reduces recurrence rates by half tant components of treatment for many types of when used in combination with chemotherapy in cancer, but their efficacy is limited by systemic the 20%-30% of women with metastatic breast toxicity and lack of tumor specificity. Conjugated cancers that overexpress the HER2 (human epi- agents combine the potent cytotoxic abilities of dermal growth factor receptor) protein. HER2- traditional therapies with the specificity of a mAb targeted therapy continues to provide break- (Figure 2). throughs; in 2012, pertuzumab, which has a Currently, there are 4 antibody–drug conjugates synergistic effect when combined with trastu- (ADCs) that have been approved by the FDA; 2 con- zumab, was approved. jugated to chemotherapeutic agents, and 2 to radiother- mAbs work via several different cellular mecha- apeutic agents. The most recent approval came in 2013 nisms, of which researchers are now gaining a better for ado-trastuzumab emtansine (T-DM1), which con- understanding, and increasingly effective agents with jugates the HER2 mAb trastuzumab to the cytotoxic 2,3 fewer side effects are being developed. agent emtansine. T-DM1 was approved for patients with HER2-positive metastatic breast cancer previ- ously treated with trastuzumab and a taxane, following Commun Oncol 2013;10:178-185 © 2013 Frontline Medical Communications DOI: 10.12788/j.cmonc.0036 the demonstration that median overall survival in pa- 178 COMMUNITY ONCOLOGY Ⅲ June 2013 www.CommunityOncology.net Practice Changers tients receiving the conjugate was in- A creased by more than 5 months, com- The first an-angiogenic agent, a mAb targeng VEGF, pared with patients receiving a The radiotherapeuc anbody bevacizumab, is approved for ibritumomab uxetan is the treatment of CRC. combination of capecitabine and approved for the treatment of 5 NHL. lapatinib. Erlonib becomes the second Genentech alone has over 25 ADCs EGFR-targeted small molecule The oncogenic BRAF mutaon inhibitor available for the in the pipeline, and these are rapidly be- is idenfied and found to be an treatment of NSCLC. important driver of certain malignancies, including coming an important component of PIK3CA melanoma. Mutaons in the gene cancer treatment, particularly as re- Trastuzumab approved for the and EGFR gene are idenfied treatment of HER2-posive and shown to be important searchers begin to improve their design breast cancer drivers of colon and lung cancer, to maximize efficacy and limit toxic side respecvely. 6,7 A second radiotherapeuc anbody, I-131 tositumomab effects. The mAb alemtuzumab An an-EGFR mAb, enters the market for NHL. becomes available for the Pannitumumab, is approved for treatment of CLL. the treatment of metastac CRC Identification of defects that drive and becomes the first agent to different cancers The first agent targeng the demonstrate the use of KRAS as First-ever targeted agent EGFR, gefinib revoluonizes a predicve biomarker. Imanib for the treatment of approved; rituximab for the the treatment of NSCLC. CML gains the fastest FDA Cancer-causing genetic changes are treatment of B-cell approval in US history. It is the malignancies referred to as “driver” events because first agent to target a specific The human genome is decoded Mutaons in the ABL gene are they confer a growth advantage to can- molecular defect – the paving the way for the idenficaon idenfied. The first conclusive evidence of Philadelphia chromosome. of new genec defects driving cancer cer cells and can be directly linked to cancer stem cells is published. and improving diagnosis and the development of a cancer. Genome treatment. sequencing technology has allowed re- 1998 2001 2004 2006 searchers to uncover many of these 1997 2002 2003 events. The most frequently altered B gene in human cancer is p53. Other The first therapeuc cancer An androgen receptor inhibitor, common mutations occur in the kinase vaccine, Sipleucel-T, is enzalutamide is approved for approved for the treatment of the treatment of late-stage enzymes that are essential to intracellular advanced prostate cancer. prostate cancer. signaling pathways. Driver events also occur in the form of chromosomal rear- Breast cancer survival is further The first inhibitor of mTOR , improved by the introducon of rangements and gene overexpression, everolimus is granted approval a second HER2-targeng mAb, by the FDA for the treatment of pertuzumab, to be used in with 2 significant examples being the advanced RCC. combinaon with trastuzumab. EML4-ALK fusion gene in non–small- The first an-cancer agent targeng a cell lung cancer, and overexpression of A second EGFR-targeted mAb, developmental pathway, the hedgehog cetuximab, is approved for the inhibitor vismodegib is approved for the HER2 gene in breast cancer. treatment of KRAS wild type paents with basal cell carcinoma. The identification of driver events CRC. has been instrumental in developing tar- A record number of Americans The first anbody-drug conjugate, Ofatumumab is the first non- are shown to be surviving T-DM1, is approved by the FDA for geted therapies and assessing which pa- radiotherapeuc mAb targeng cancer according to NCI and the treatment of breast cancer. It tients benefit the most, and a number of CD20 to be approved for the CDC data. combines the HER2 mAb with a treatment of CLL. cytotoxic agent (DM1). Ipilimumab, a mAb targeng tests have been approved by the FDA CTLA4, becomes the first cancer for this purpose (Table 3). Continual as- agent to target the immune Acvang mutaons in the The transforming EML4-ALK system, in order to help HER2 gene are idenfied, which sessment of the cancer genome is also fusion gene is idenfied as an paents with metastac could mean that HER2-negave important driver of lung cancer. melanoma. paents also benefit from important as subsequent mutations HER2-targeted agents. can develop in response to targeted therapy that may drive resistance.8 2012 2007 2009 2010 2011 2013 Inhibiting angiogenesis Tumors require oxygen and nutrients FIGURE 1 Timeline of developments in targeted therapies, beginning with the FDA’s approval of rituximab in 1997 through 2013 to date, with the approval of T-DM1 for breast cancer. from their surrounding environment to Abbreviations and definitions: ABL, gene that encodes abelson murine leukemia viral oncogene homolog 1; be able to grow and they initially obtain BRAF, gene that encodes B-Raf kinase; CDC, Centers for Disease Control and Prevention; CLL, chronic them through diffusion. However, they lymphocytic leukemia; CML, chronic myelogenous leukemia; CRC, colorectal carcinoma; CTLA4, cytotoxic T-lymphocyte antigen-4; EGFR, epidermal growth factor receptor; EML4-ALK, fusion between echinoderm are unable to grow beyond 2 mm with- microtubule-associated protein-like 4 and anaplastic lymphoma kinase genes; FDA, Food and Drug Admin- out stimulating the growth of new blood istration; KRAS, gene encoding a member of the Ras family of kinases; mAb, monoclonal antibody; NCI, vessels (a process called angiogenesis) to National Cancer Institute; NHL, non-Hodgkin lymphoma; NSCLC,
Load more

Recommended publications
  • Potential High-Impact Interventions Report Priority Area 02: Cancer
    AHRQ Healthcare Horizon Scanning System – Potential High-Impact Interventions Report Priority Area 02: Cancer Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 540 Gaither Road Rockville, MD 20850 www.ahrq.gov Contract No. HHSA290201000006C Prepared by: ECRI Institute 5200 Butler Pike Plymouth Meeting, PA 19462 December 2012 Statement of Funding and Purpose This report incorporates data collected during implementation of the Agency for Healthcare Research and Quality (AHRQ) Healthcare Horizon Scanning System by ECRI Institute under contract to AHRQ, Rockville, MD (Contract No. HHSA290201000006C). The findings and conclusions in this document are those of the authors, who are responsible for its content, and do not necessarily represent the views of AHRQ. No statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services. This report’s content should not be construed as either endorsements or rejections of specific interventions. As topics are entered into the System, individual topic profiles are developed for technologies and programs that appear to be close to diffusion into practice in the United States. Those reports are sent to various experts with clinical, health systems, health administration, and/or research backgrounds for comment and opinions about potential for impact. The comments and opinions received are then considered and synthesized by ECRI Institute to identify interventions that experts deemed, through the comment process, to have potential for high impact. Please see the methods section for more details about this process. This report is produced twice annually and topics included may change depending on expert comments received on interventions issued for comment during the preceding 6 months.
    [Show full text]
  • Vandetanib (ZD6474), an Inhibitor of VEGFR and EGFR Signalling, As a Novel Molecular-Targeted Therapy Against Cholangiocarcinoma
    British Journal of Cancer (2009) 100, 1257 – 1266 & 2009 Cancer Research UK All rights reserved 0007 – 0920/09 $32.00 www.bjcancer.com Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma 1,2 3 1 4 2 3 ,1,3 D Yoshikawa , H Ojima , A Kokubu , T Ochiya , S Kasai , S Hirohashi and T Shibata* 1 2 Cancer Genomics Project, National Cancer Center Research Institute, Tokyo, Japan; Division of Gastroenterological and General Surgery, Department of Surgery, Asahikawa Medical College, Asahikawa, Japan; 3Pathology Division, National Cancer Center Research Institute, Tokyo, Japan; 4Section for Studies on Metastasis, National Cancer Center Research Institute, Tokyo, Japan Cholangiocarcinoma is an intractable cancer, with no effective therapy other than surgical resection. Elevated vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) expressions are associated with the progression of cholangiocarcinoma. We therefore examined whether inhibition of VEGFR and EGFR could be a potential therapeutic target for cholangiocarcinoma. Vandetanib (ZD6474, ZACTIMA), a VEGFR-2/EGFR inhibitor, was evaluated. Four human cholangiocarcinoma cell lines were molecularly characterised and investigated for their response to vandetanib. In vitro, two cell lines (OZ and HuCCT1), both of which harboured KRAS mutation, were refractory to vandetanib, one cell line (TGBC24TKB) was somewhat resistant, and another cell line (TKKK) was sensitive. The most sensitive cell line (TKKK) had EGFR amplification. Vandetanib significantly À1 À1 À1 À1 inhibited the growth of TKKK xenografts at doses X12.5 mg kg day (Po0.05), but higher doses (50 mg kg day , Po0.05) of À1 À1 vandetanib were required to inhibit the growth of OZ xenografts.
    [Show full text]
  • Gefitinib and Afatinib Show Potential Efficacy for Fanconi Anemia−Related Head and Neck Cancer
    Published OnlineFirst January 31, 2020; DOI: 10.1158/1078-0432.CCR-19-1625 CLINICAL CANCER RESEARCH | TRANSLATIONAL CANCER MECHANISMS AND THERAPY Gefitinib and Afatinib Show Potential Efficacy for Fanconi Anemia–Related Head and Neck Cancer Helena Montanuy1, Agueda Martínez-Barriocanal2,3, Jose Antonio Casado4,5, Llorenc¸ Rovirosa1, Maria Jose Ramírez1,4,6, Rocío Nieto2, Carlos Carrascoso-Rubio4,5, Pau Riera6,7, Alan Gonzalez 8, Enrique Lerma7, Adriana Lasa4,6, Jordi Carreras-Puigvert9, Thomas Helleday9, Juan A. Bueren4,5, Diego Arango2,3, Jordi Minguillon 1,4,5, and Jordi Surralles 1,4,5 ABSTRACT ◥ Purpose: Fanconi anemia rare disease is characterized by bone two best candidates, gefitinib and afatinib, EGFR inhibitors marrow failure and a high predisposition to solid tumors, especially approved for non–small cell lung cancer (NSCLC), displayed head and neck squamous cell carcinoma (HNSCC). Patients with nontumor/tumor IC50 ratios of approximately 400 and approx- Fanconi anemia with HNSCC are not eligible for conventional imately 100 times, respectively. Neither gefitinib nor afatinib therapies due to high toxicity in healthy cells, predominantly activated the Fanconi anemia signaling pathway or induced hematotoxicity, and the only treatment currently available is sur- chromosomal fragility in Fanconi anemia cell lines. Importantly, gical resection. In this work, we searched and validated two already both drugs inhibited tumor growth in xenograft experiments in approved drugs as new potential therapies for HNSCC in patients immunodeficient mice using two Fanconi anemia patient– with Fanconi anemia. derived HNSCCs. Finally, in vivo toxicity studies in Fanca- Experimental Design: We conducted a high-content screening deficient mice showed that administration of gefitinib or afatinib of 3,802 drugs in a FANCA-deficient tumor cell line to identify was well-tolerated, displayed manageable side effects, no toxicity nongenotoxic drugs with cytotoxic/cytostatic activity.
    [Show full text]
  • Management of Chronic Myelogenous Leukemia in Pregnancy
    ANTICANCER RESEARCH 35: 1-12 (2015) Review Management of Chronic Myelogenous Leukemia in Pregnancy AMIT BHANDARI, KATRINA ROLEN and BINAY KUMAR SHAH Cancer Center and Blood Institute, St. Joseph Regional Medical Center, Lewiston, ID, U.S.A. Abstract. Discovery of tyrosine kinase inhibitors has led to Leukemia in pregnancy is a rare condition, with an annual improvement in survival of chronic myelogenous leukemia incidence of 1-2/100,000 pregnancies (8). Since the first (CML) patients. Many young CML patients encounter administration of imatinib (the first of the TKIs) to patients pregnancy during their lifetime. Tyrosine kinase inhibitors with CML in June 1998, it is estimated that there have now inhibit several proteins that are known to have important been 250,000 patient years of exposure to the drug (mostly functions in gonadal development, implantation and fetal in patients with CML) (9). TKIs not only target BCR-ABL development, thus increasing the risk of embryo toxicities. tyrosine kinase but also c-kit, platelet derived growth factors Studies have shown imatinib to be embryotoxic in animals with receptors α and β (PDGFR-α/β), ARG and c-FMS (10). varying effects in fertility. Since pregnancy is rare in CML, Several of these proteins are known to have functions that there are no randomized controlled trials to address the may be important in gonadal development, implantation and optimal management of this condition. However, there are fetal development (11-15). Despite this fact, there is still only several case reports and case series on CML in pregnancy. At limited information on the effects of imatinib on fertility the present time, there is no consensus on how to manage and/or pregnancy.
    [Show full text]
  • Nilotinib (Tasigna®) EOCCO POLICY
    nilotinib (Tasigna®) EOCCO POLICY Policy Type: PA/SP Pharmacy Coverage Policy: EOCCO136 Description Nilotinib (Tasigna) is a Bcr-Abl kinase inhibitor that binds to, and stabilizes, the inactive conformation of the kinase domain of the Abl protein. Length of Authorization Initial: Three months Renewal: 12 months Quantity Limits Product Name Dosage Form Indication Quantity Limit Newly diagnosed OR resistant/ intolerant 50 mg capsules 112 capsules/28 days Ph+ CML in chronic phase nilotinib 150 mg capsules Newly diagnosed Ph+ CML in chronic phase 112 capsules/28 days (Tasigna) Resistant or intolerant Ph + CML 200 mg capsules 112 capsules/28 days Gastrointestinal Stromal Tumors (GIST) Initial Evaluation I. Nilotinib (Tasigna) may be considered medically necessary when the following criteria are met: A. Medication is prescribed by, or in consultation with, an oncologist; AND B. Medication will not be used in combination with other oncologic medications (i.e., will be used as monotherapy); AND C. A diagnosis of one of the following: 1. Chronic myelogenous leukemia (CML) ; AND i. Member is newly diagnosed with Philadelphia chromosome-positive (Ph+) or BCR-ABL1 mutation positive CML in chronic phase; OR ii. Member is diagnosed with chronic OR accelerated phase Ph+ or BCR-ABL1 mutation positive CML; AND a. Member is 18 years of age or older; AND b. Treatment with a tyrosine kinase inhibitor [e.g. imatinib (Gleevec)] has been ineffective, contraindicated, or not tolerated; OR iii. Member is diagnosed with chronic phase Ph+ or BCR-ABL1 mutation positive CML; AND a. Member is one year of age or older; AND 1 nilotinib (Tasigna®) EOCCO POLICY b.
    [Show full text]
  • A Retrospective Analysis of RET Translocation, Gene Copy Number
    Platt et al. BMC Cancer (2015) 15:171 DOI 10.1186/s12885-015-1146-8 RESEARCH ARTICLE Open Access A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies Adam Platt1*, John Morten2, Qunsheng Ji3, Paul Elvin2, Chris Womack2, Xinying Su3, Emma Donald2, Neil Gray2, Jessica Read2, Graham Bigley2, Laura Blockley2, Carl Cresswell2, Angela Dale2, Amanda Davies2, Tianwei Zhang3, Shuqiong Fan3, Haihua Fu3, Amanda Gladwin2, Grace Harrod2, James Stevens2, Victoria Williams2, Qingqing Ye3, Li Zheng3, Richard de Boer4, Roy S Herbst5, Jin-Soo Lee6 and James Vasselli7,8 Abstract Background: To determine the prevalence of RET rearrangement genes, RET copy number gains and expression in tumor samples from four Phase III non-small-cell lung cancer (NSCLC) trials of vandetanib, a selective inhibitor of VEGFR, RET and EGFR signaling, and to determine any association with outcome to vandetanib treatment. Methods: Archival tumor samples from the ZODIAC (NCT00312377, vandetanib ± docetaxel), ZEAL (NCT00418886, vandetanib ± pemetrexed), ZEPHYR (NCT00404924, vandetanib vs placebo) and ZEST (NCT00364351, vandetanib vs erlotinib) studies were evaluated by fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) in 944 and 1102 patients. Results: The prevalence of RET rearrangements by FISH was 0.7% (95% CI 0.3–1.5%) among patients with a known result. Seven tumor samples were positive for RET rearrangements (vandetanib, n = 3; comparator, n = 4). 2.8% (n =26) of samples had RET amplification (innumerable RET clusters, or ≥7 copies in > 10% of tumor cells), 8.1% (n = 76) had low RET gene copy number gain (4–6copiesin≥40% of tumor cells) and 8.3% (n = 92) were RET expression positive (signal intensity ++ or +++ in >10% of tumor cells).
    [Show full text]
  • Tasigna, INN-Nilotinib
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Tasigna 50 mg hard capsules Tasigna 200 mg hard capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Tasigna 50 mg hard capsules One hard capsule contains 50 mg nilotinib (as hydrochloride monohydrate). Excipient with known effect One hard capsule contains 39.03 mg lactose monohydrate. Tasigna 200 mg hard capsules One hard capsule contains 200 mg nilotinib (as hydrochloride monohydrate). Excipient with known effect One hard capsule contains 156.11 mg lactose monohydrate. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Hard capsule. Tasigna 50 mg hard capsules White to yellowish powder in hard gelatin capsule with red opaque cap and light yellow opaque body, size 4 with black radial imprint “NVR/ABL” on cap. Tasigna 200 mg hard capsules White to yellowish powder in light yellow opaque hard gelatin capsules, size 0 with red axial imprint “NVR/TKI”. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Tasigna is indicated for the treatment of: - adult and paediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia (CML) in the chronic phase, - adult patients with chronic phase and accelerated phase Philadelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib. Efficacy data in patients with CML in blast crisis are not available, - paediatric patients with chronic phase Philadelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib. 2 4.2 Posology and method of administration Therapy should be initiated by a physician experienced in the diagnosis and the treatment of patients with CML.
    [Show full text]
  • The Effects of Combination Treatments on Drug Resistance in Chronic Myeloid Leukaemia: an Evaluation of the Tyrosine Kinase Inhibitors Axitinib and Asciminib H
    Lindström and Friedman BMC Cancer (2020) 20:397 https://doi.org/10.1186/s12885-020-06782-9 RESEARCH ARTICLE Open Access The effects of combination treatments on drug resistance in chronic myeloid leukaemia: an evaluation of the tyrosine kinase inhibitors axitinib and asciminib H. Jonathan G. Lindström and Ran Friedman* Abstract Background: Chronic myeloid leukaemia is in principle a treatable malignancy but drug resistance is lowering survival. Recent drug discoveries have opened up new options for drug combinations, which is a concept used in other areas for preventing drug resistance. Two of these are (I) Axitinib, which inhibits the T315I mutation of BCR-ABL1, a main source of drug resistance, and (II) Asciminib, which has been developed as an allosteric BCR-ABL1 inhibitor, targeting an entirely different binding site, and as such does not compete for binding with other drugs. These drugs offer new treatment options. Methods: We measured the proliferation of KCL-22 cells exposed to imatinib–dasatinib, imatinib–asciminib and dasatinib–asciminib combinations and calculated combination index graphs for each case. Moreover, using the median–effect equation we calculated how much axitinib can reduce the growth advantage of T315I mutant clones in combination with available drugs. In addition, we calculated how much the total drug burden could be reduced by combinations using asciminib and other drugs, and evaluated which mutations such combinations might be sensitive to. Results: Asciminib had synergistic interactions with imatinib or dasatinib in KCL-22 cells at high degrees of inhibition. Interestingly, some antagonism between asciminib and the other drugs was present at lower degrees on inhibition.
    [Show full text]
  • Bridging from Preclinical to Clinical Studies for Tyrosine Kinase Inhibitors Based on Pharmacokinetics/Pharmacodynamics and Toxicokinetics/Toxicodynamics
    Drug Metab. Pharmacokinet. 26 (6): 612­620 (2011). Copyright © 2011 by the Japanese Society for the Study of Xenobiotics (JSSX) Regular Article Bridging from Preclinical to Clinical Studies for Tyrosine Kinase Inhibitors Based on Pharmacokinetics/Pharmacodynamics and Toxicokinetics/Toxicodynamics Azusa HOSHINO-YOSHINO1,2,MotohiroKATO2,KohnosukeNAKANO2, Masaki ISHIGAI2,ToshiyukiKUDO1 and Kiyomi ITO1,* 1Research Institute of Pharmaceutical Sciences, Musashino University, Tokyo, Japan 2Pre-clinical Research Department, Chugai Pharmaceutical Co. Ltd., Kanagawa, Japan Full text of this paper is available at http://www.jstage.jst.go.jp/browse/dmpk Summary: The purpose of this study was to provide a pharmacokinetics/pharmacodynamics and toxi- cokinetics/toxicodynamics bridging of kinase inhibitors by identifying the relationship between their clinical and preclinical (rat, dog, and monkey) data on exposure and efficacy/toxicity. For the eight kinase inhibitors approved in Japan (imatinib, gefitinib, erlotinib, sorafenib, sunitinib, nilotinib, dasatinib, and lapatinib), the human unbound area under the concentration-time curve at steady state (AUCss,u) at the clinical dose correlated well with animal AUCss,u at the no-observed-adverse-effect level (NOAEL) or maximum tolerated dose (MTD). The best correlation was observed for rat AUCss,u at the MTD (p < 0.001). Emax model analysis was performed using the efficacy of each drug in xenograft mice, and the efficacy at the human AUC of the clinical dose was evaluated. The predicted efficacy at the human AUC of the clinical dose varied from far below Emax to around Emax even in the tumor for which use of the drugs had been accepted. These results suggest that rat AUCss,u attheMTD,butnottheefficacy in xenograft mice, may be a useful parameter to estimate the human clinical dose of kinase inhibitors, which seems to be currently determined by toxicity rather than efficacy.
    [Show full text]
  • Thyrosin Kinase Inhibitors: Nilotinib F
    Hematology Meeting Reports 2008;2(5):22-26 SESSION II F. Castagnetti Thyrosin kinase inhibitors: nilotinib F. Palandri G. Gugliotta A. Poerio M. Amabile S. Soverini G. Martinelli M. Baccarani G. Rosti Nilotinib is an aminopyrimidine The only BCR-ABL mutant that derivative that inhibits the tyro- was not inhibited by nilotinib was Department of Hematology, St. Orsola University Hospital sine kinase activity of the T315I. Bologna, Italy chimeric protein BCR-ABL. The unregulated activity of the ABL tyrosine kinase in the BCR-ABL Pharmacokinetic profile protein causes CML, and inhibi- tion of tyrosine kinase activity is The extent of nilotinib absorp- key to the treatment of the disor- tion following oral administration der. Nilotinib acts via competitive was estimated to be approximate- inhibition at the binding site of the ly 30%. The bioavailability of BCR-ABL protein in a similar nilotinib was increased when manner to imatinib, although nilo- given with a meal. Compared to tinib has a higher binding affinity the fasted state, the systemic and selectivity for the ABL exposure (AUC) in the fed state kinase. Once bound to the ATP- increased by 15% (drug adminis- binding site, nilotinib inhibits tered 2 hours after a light meal), tyrosine phosphorylation of pro- 29% (30 minutes after a light teins involved in BCR-ABL- meal), or 82% (30 minutes after a mediated intracellular signal high fat meal), and the Cmax transduction. increased by 33% (2 hours after a The inhibitory activity of nilo- light meal), 55% (30 minutes tinib in CML cell is markedly after a light meal), or 112% (30 higher than that of imatinib.
    [Show full text]
  • Metabolic Imaging Allows Early Prediction of Response to Vandetanib
    Metabolic Imaging Allows Early Prediction of Response to Vandetanib Martin A. Walter1,2,MatthiasR.Benz2,IsabelJ.Hildebrandt2, Rachel E. Laing2, Verena Hartung3, Robert D. Damoiseaux4, Andreas Bockisch3, Michael E. Phelps2,JohannesCzernin2, and Wolfgang A. Weber2,5 1Institute of Nuclear Medicine, University Hospital, Bern, Switzerland; 2Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California; 3Institute of Nuclear Medicine, University Hospital, Essen, Germany; 4Molecular Shared Screening Resources, UCLA, Los Angeles, California; and 5Department of Nuclear Medicine, University Hospital, Freiburg, Germany The RET (rearranged-during-transfection protein) protoonco- The RET (rearranged-during-transfection protein) proto- gene triggers multiple intracellular signaling cascades regulat- oncogene, located on chromosome 10q11.2, encodes for ing cell cycle progression and cellular metabolism. We therefore a tyrosine kinase of the cadherin superfamily that activates hypothesized that metabolic imaging could allow noninvasive detection of response to the RET inhibitor vandetanib in vivo. multiple intracellular signaling cascades regulating cell sur- Methods: The effects of vandetanib treatment on the full- vival, differentiation, proliferation, migration, and chemo- genome expression and the metabolic profile were analyzed taxis (1). Gain-of-function mutations in the RET gene result in the human medullary thyroid cancer cell line TT. In vitro, tran- in uncontrolled growth and cause human cancers and scriptional changes of pathways regulating cell cycle progres- cancer syndromes, such as Hu¨rthle cell cancer, sporadic sion and glucose, dopa, and thymidine metabolism were papillary thyroid carcinoma, familial medullary thyroid correlated to the results of cell cycle analysis and the uptake of 3H-deoxyglucose, 3H-3,4-dihydroxy-L-phenylalanine, and carcinoma, and multiple endocrine neoplasia types 2A 3H-thymidine under vandetanib treatment.
    [Show full text]
  • Novel Approaches for Efficient Delivery of Tyrosine Kinase Inhibitors
    J Pharm Pharm Sci (www.cspsCanada.org) 22, 37 - 48, 2019 Novel Approaches for Efficient Delivery of Tyrosine Kinase Inhibitors Zahra moradpour1, Leila Barghi2 1Department of Pharmaceutical biotechnology and 2Department of Pharmaceutics, School of Pharmacy, Urmia University of medical sciences, Urmia, Iran. Received, September 15, 2018; Revised October 25, 2018; Accepted, January 7, 2019; Published, January 9, 2018. ABSTRACT - Epidermal growth factor receptors (EGFRs) have potential to be considered as therapeutic target for cancer treatment especially in cancer patients with overexpression of EGFR. Cetuximab as a first monoclonal antibody and Imatinib as the first small molecule tyrosine kinase inhibitor (SMTKI) were approved by FDA in 1998 and 2001. About 28 SMTKIs have been approved until 2015 and a large number of compound with kinase inhibitory activity are at the different phases of clinical trials. Although Kinase inhibitors target specific intracellular pathways, their tissue or cellular distribution are not specific. So treatment with these drugs causes serious dose dependent side effects. Targeted delivery of kinase inhibitors via dendrimers, polymeric nanoparticles, magnetic nanoparticles and lipid based delivery systems such as liposomes, solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) can lead to reduction of side effects and improving therapeutic efficacy of the drugs in the target organs. Furthermore formulation of these drugs is challenged by their physicochemical properties such as solubility and dissolution rate. The main approaches in order to increase dissolution rate, are particle size reduction, self-emulsification, cyclodextrin complexation, crystal modification and amorphous solid dispersion. Synergistic therapeutic effect, decreased side effects and drug resistant, reduced cost and increased patient compliance are the advantages associated with using combination therapy especially in the treatment of cancer.
    [Show full text]